Drug Trial Radar · NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 5, 2024
Primary completion
Sep 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- MedSIRAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stemline Therapeutics, Inc.
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival. Rigorous eligibility criteria based on specific co-morbidities and clinicopathologic features of their disease have been designed to minimize the risk of patients participating in this study. The anticipated favorable clinical benefits of elacestrant combined with everolimus are projected to outweigh the risks of this treatment. This study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.
Conditions
- Advanced Breast Cancer
- ER-positive Breast Cancer
- HER2-negative Breast Cancer
- ESR1 Gene Mutation
Interventions
EverolimusDrug
Patients will receive 7.5 mg of everolimus orally once daily.
ElacestrantDrug
Patients will receive elacestrant 345 mg orally once daily
PlaceboDrug
Patients will receive placebo orally once daily
Auxiliary Medicinal Product - DexamethasoneDrug
10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analoguesDrug
According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).Time frame: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.
Locations
104 sites in 9 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Austria · Recruiting
Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria · Recruiting
Ordination Priv.-Doz. Dr. Michael Hubalek
Schwaz, Austria · Recruiting
Medical University of Vienna
Vienna, Austria · Not yet recruiting
Tacchini Instituto de Pesquisa
Bento Gonçalves, Brazil · Not yet recruiting
Hospital Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Brazil · Not yet recruiting
Catarina Pesquisa Clínica - Neoplasias Litoral
Itajaí, Brazil · Not yet recruiting
UPCO - Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil · Not yet recruiting
NOB Ondina
Salvador, Brazil · Not yet recruiting
Masaryk Memorial Cancer Institute
Brno, Czechia · Recruiting
Multiscan Nemocnice Horovice
Hořovice, Czechia · Recruiting
University Hospital Olomouc
Olomouc, Czechia · Not yet recruiting
General University Hospital Prague
Prague, Czechia · Recruiting
Motol University Hospital
Prague, Czechia · Recruiting
Tomas Bata Regional Hospital in Zlin
Zlín, Czechia · Recruiting
Polyclinique Bordeaux Nord Aquitaine
Bordeau, France · Recruiting
Institut Bergonié Bordeaux
Bordeaux, France · Not yet recruiting
Centre Georges François Leclerc
Dijon, France · Recruiting
Centre Hospitalier de Limoges
Limoges, France · Recruiting
CHU Lyon Sud
Lyon, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Not yet recruiting
APHP Tenon
Paris, France · Not yet recruiting
Hospital prive des Cotes d'Amor
Plérin, France · Recruiting
CHU Saint Etienne
Saint-Priest-en-Jarez, France · Recruiting
Centre Paul Strauss
Strasbourg, France · Recruiting
IUCT Oncopole
Toulouse, France · Recruiting
Institute de Cancerologie de Lorraine - Nancy
Vandœuvre-lès-Nancy, France · Recruiting
MVZ Klinikum Aschaffenburg
Aschaffenburg, Germany · Not yet recruiting
Hämatologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Germany · Not yet recruiting
Städtisches Klinikum Dessau
Dessau, Germany · Not yet recruiting
Universitätsklinikum Dusseldorf
Düsseldorf, Germany · Not yet recruiting
Universitätsklinikum Essen
Essen, Germany · Not yet recruiting
MVZ II der Niels Stensen Kliniken
Georgsmarienhütte, Germany · Recruiting
Klinikum Worms - Frauenklinik
Worms, Germany · Recruiting
University General Hospital Alexandroupoli
Alexandroupoli, Greece · Recruiting
251 Air Force General Hospital
Athens, Greece · Recruiting
Aretaeio Hospital
Athens, Greece · Recruiting
Attikon University Hospital
Athens, Greece · Recruiting
Metropolitan General Hospital 4th department
Athens, Greece · Recruiting
University General Hospital of Heraklion
Heraklion, Greece · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.